Physician and Institution Preparedness for CAR T-Cell Therapy

CAR T-cell therapy has been at the forefront of a revolutionary paradigm shift in cancer treatment and the oncology space through immunotherapies. While effective, there are numerous challenges in delivering CAR T-cell therapy to each patient, including the synchronization of a series of moving parts and the expenditure of hundreds of thousands of dollars. Aside from its success, there are potentially severe adverse effects of CAR T-cell therapy. HRA’s syndicated study reveals how data, predictive analytics, and artificial intelligence can better prepare the industry for CAR T-cell therapy.
In conducting research, HRA used its expertise in the digital landscape and drove the social media conversation about CAR T-cell therapy, which included patients, caregivers, and HCPs expressing fear about potential adverse events. Our quantitative research with HCPs revealed that a majority are likely to use CAR T-cell therapy as a first-line treatment for cancer patients. Further research revealed that most hospitals offering CAR T-cell therapy host an in-house analytics department. This report reveals key insights on what pharmaceutical companies can do to support CAR T-cell therapy, and make an impact not only on the industry, but on the lives of every cancer patient saved by CAR T-cell therapy.
Price: $695.00
My Cart
Subtotal $0.00
Copyright HRA Data Driven Intelligence 1974-2019 HRA Data Driven Intelligence, LLC. All rights Reserved.